About Professor Heimburger
Prof. Norbert Heimburger was a CSL Behring employee for over three decades and devoted his work to blood coagulation. During that time, he characterized and purified a large number of plasma proteins and was instrumental in making these available to the medical community as therapeutic options. One of his major contributions in this area was the development of virus-safe plasma products through the introduction of pasteurization.
About the World Federation of Hemophilia
The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and related bleeding disorders. Since it was established in 1963, the WFH has grown into a truly global network with member organizations in 113 countries and official recognition from the World Health Organization. The WFH works in partnership with healthcare professionals and people with hemophilia, governments and regulators, industry, and foundations, to improve hemophilia care throughout the world. For more information, visit www.wfh.org.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and hereditary angioedema. The company's products are also used to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company with headquarters in Melbourne, Australia. For m
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved